Incyte Corporation trades at $96.74, up 6.6% over the past month despite a modest 0.4% dip this week. The biotech firm reports Q1 2026 results on April 28.
Short interest sits at 5.79% of float. That's low for biotech. Shorts added 700,000 shares over the past month, a 4.6% increase. Cost to borrow remains negligible at 0.44%. Utilization dropped to 6.42% from 6.85% a week ago. These aren't crowded short positions.
Options sentiment ticked higher. The put/call ratio rose to 0.73 from a 20-day average of 0.67. More puts are trading than usual. That suggests modest hedging activity ahead of earnings.
The company posted $5.57 billion in revenue with $1.28 billion in net income last year. ORTEX's stock score of 80.24 ranks Incyte in the top quintile. Analysts see 11.6% upside from current levels. The $19.3 billion market cap positions Incyte as a mid-tier biotech player.
Technical indicators show neutral momentum. RSI14 stands at 51.65, right in the middle zone. The stock trades neither overbought nor oversold. Days to cover sits at 5.7 days, offering no squeeze pressure.
No insider transactions appeared over the past 90 days above ORTEX's significance threshold. That's common in the quiet period before earnings.
With earnings five days away, the setup looks calm. Short interest is light. Options activity shows routine hedging. Fundamentals remain solid based on the composite score.
This is not financial advice. ORTEX data may contain errors.
See the live data behind this article on ORTEX.
Open INCY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
